Myocyte-specific enhancer factor 2 (MEF2) (MEF2)

Myocyte-specific enhancer factor 2 (MEF2) is a family of transcription factors, including MEF2A, B, C, and D, that serve as master regulators of cellular differentiation and organogenesis (UniProt: Q06413). These proteins belong to the MADS-box superfamily and are characterized by their ability to bind to A/T-rich DNA sequences in the promoter regions of genes essential for muscle and neural development (NCBI Gene: 4208). MEF2 integrates various signaling pathways, such as the calcium/calcineurin and MAP kinase pathways, to control gene expression programs involved in myogenesis, cardiogenesis, and neurogenesis (PubMed: 17613554). In the cardiovascular system, MEF2 is critical for heart development and its dysregulation is a hallmark of cardiac hypertrophy and heart failure (PubMed: 11050320). In the brain, MEF2 regulates neuronal survival and synaptic pruning, with its dysfunction linked to neurodegenerative diseases like Alzheimer's and Parkinson's (PubMed: 18354481). While direct inhibitors of MEF2 are still in early research, the factor is frequently targeted indirectly through drugs that inhibit its co-repressors, such as Class II histone deacetylases (HDACs), or its activators like calcineurin (PubMed: 11050320). Consequently, MEF2 represents a significant therapeutic node for treating muscle wasting, heart disease, and certain cancers where it influences cell proliferation and survival (PubMed: 25135857). Its role as a molecular switch makes it a high-interest target for regenerative medicine and oncology.

Other names

MADS-box transcription factorRSRFRelated to serum response factorMEF-2MEF2AMEF2BMEF2CMEF2D

Transcriptional activation or repression through binding to CTA(A/T)4TAG DNA sequences and recruitment of co-regulators like histone deacetylases (HDACs) or histone acetyltransferases (HATs) (PubMed: 11050320).